BTG ANNOUNCES AVAILABILITY OF A NOVEL CHALCOGENIDE LASER FOR LICENSE

Main Menu | News By Date | News By Supplier | News By Category | About Us

BTG ANNOUNCES AVAILABILITY OF A NOVEL CHALCOGENIDE LASER FOR LICENSE
25 September 2006 - BTG

BTG, the IP and technology commercialisation company, today announced that it is offering for license patented, fundamental chalcogenide semiconductor laser technology, which can provide broad functionality for sensing and laser ablation applications.

The technology package, originally developed at the Lawrence Livermore National Laboratory, provides a versatile, tuneable, and more economical alternative to products already available on the market. A commercial prototype is currently under development at Canada’s INO and will be available to demonstrate this technology.

The laser embodies a variety of features that maximize functionality. Its configuration is versatile both in application flexibility and potential implementation, providing an array of advantages. Compared to currently available lasers in the 2-3 micron wavelength range, this laser’s properties can be easily adjusted by changing either the doping material or the crystal material. Just as importantly, this technology promises to be a low-cost alternative to other existing solid-state lasers because it can utilize low-cost materials, existing pump sources, and established crystal growth/fabrication techniques. These characteristics make the laser applicable to the medical, sensing and military fields, as well as a host of others.

“This laser solution fills a gap that exists in the 2-3 micron wavelength range, where there is a need for small, broadly tuneable, cost-effective solutions,” said Dr. William Krupke, co-inventor of this novel laser, co-founder of the Laser Directorate at the Lawrence Livermore National Laboratory, and consultant to several high technology private companies.

Jay Kshatri, Vice President of BTG’s Semiconductors and Optoelectronics Business Unit said, “We are excited to be working with such well-respected groups as the Lawrence Livermore National Laboratory and INO to bring this solution to market. We look forward to continuing our relationship with these great institutions as we support this technology through the prototype stage and into commercialisation.”

http://www.btgplc.com

About: BTG
BTG is an intellectual property and technology commercialisation company that operates internationally. BTG creates value by investing in intellectual property and technology development, and in early stage ventures. We realise value through technology licensing, patent assertion and sale of equity investments. Through a multidisciplinary approach, we apply intellectual property and commercial expertise, together with specialist skills in science and technology, to create major product opportunities in the health and high tech sectors. BTG has commercialised important innovations, including Magnetic Resonance Imaging, Multilevel Cell Memory, Campath (alemtuzumab), the first monoclonal antibody treatment for chronic lymphocytic leukaemia, and recombinant Factor IX blood clotting protein. BTG operates through wholly owned subsidiaries BTG International Ltd and BTG International Inc in the UK and USA, respectively.

More News:
  • For September 2006
  • From BTG
  • For Polymer OLED Devices